Nuvation Bio Inc. (NUVB) shares experienced a significant after-hours plunge of 6.68% on Monday. The sharp decline followed the release of the company's fourth-quarter financial results.
The biotechnology company reported a quarterly loss of $0.11 per share, which missed the analyst consensus estimate of a $0.09 loss by 22.22 percent. This earnings miss appears to be the primary driver behind the negative investor sentiment in the extended trading session. While the company's quarterly sales of $41.865 million surpassed estimates, the wider-than-expected loss weighed on the stock.
Nuvation Bio's net loss for the quarter was reported at $36.6 million. The market's reaction highlights the sensitivity of biotech stocks to earnings performance relative to Wall Street expectations, particularly for companies in the commercial stage like Nuvation Bio.
Comments